Post-Market Reporting Duties of Importers, Hospitals and Researchers in Canada

1. Key takeaways

The Canadian post-market reporting system involves four categories of parties: manufacturers (sections 59 to 61), importers (sections 59 to 61, reporting separately from the manufacturer), hospitals (section 62, which under Health Canada’s explanation must submit a written report within 30 days after a serious device incident is documented), and qualified researchers (under the ITA, who must report a serious adverse event within 72 hours of discovering it).

• The word “each” in section 59(1) makes the importer an independent reporting party, not a relay for the manufacturer.
• Distributors are not directly bound by mandatory problem reporting, but the timelines they set for reporting problems to the manufacturer or importer should be proportionate to the risk level.
• GUI-0065 recommends that, before a preliminary risk estimate is available, each reported problem be handled within the timeframe corresponding to the highest risk level.
• The hospital reporting deadline is 30 days, running from the point the serious device incident is documented, and early reporting is encouraged.
• The 72-hour researcher deadline under the ITA runs in parallel with the company’s own 10-day / 30-day clocks.
• Under section 68.03(2)(a), importers must comply with the mandatory problem reporting obligations of sections 59 to 61.

2. Legal basis

The reporting duties described in this article come from different layers of the framework: the Regulations, Health Canada’s post-market requirements pages for hospitals and importers, the ITA guidance for researchers, and GUI-0065 for problem investigation. The table below lists each source relied on.

3. Expert insights

The Canadian reporting system does not place the burden on one actor alone. Understanding how the four clocks interact — and where they differ in their starting points — is the core of this article.

Insight 1: “each” means the importer is an independent party, not a repeater for the manufacturer.

Section 59(1) requires the manufacturer and the importer to each submit preliminary and final reports. An importer cannot claim that “the manufacturer has already reported” and thereby discharge its own obligation. The importer’s duty exists independently, and its process, templates and records must exist independently too.

Insight 2: distributors carry no direct mandatory reporting duty, but they face transmission timeframes.

According to GUI-0065, distributors are not bound by the mandatory problem reporting requirements; however, the timeframe a distributor sets for reporting problems to the manufacturer or the importer should be proportionate to the risk level. GUI-0065 also recommends that, before a preliminary risk estimate is available, each reported problem be handled according to the timeframe corresponding to the highest risk tier, to ensure compliance with the shortest mandatory reporting timelines. In practice this means a distributor’s internal routing must not become the bottleneck that causes the manufacturer or importer to miss its own clock.

Insight 3: the hospital deadline is 30 days, and it starts from the point the incident is documented.

According to Health Canada’s explanation, hospitals must submit the mandatory report in writing within 30 days after a serious device incident is documented, and early reporting is encouraged. This starting point differs from the manufacturer and importer rule, where the 10-day and 30-day clocks run from the point of becoming aware of the incident. A supply chain that includes hospitals should make this distinction explicit in its communication materials.

Insight 4: the 72-hour researcher clock under the ITA runs in parallel with the corporate 10-day / 30-day clocks.

Under Health Canada’s ITA guidance, a qualified researcher must report a serious adverse event within 72 hours of discovering it, to Health Canada, the manufacturer and the importer. At the same time, the manufacturer and the importer remain subject to the domestic incident timelines of section 60(1)(a): a preliminary report within 10 days or 30 days. The two lines are timed separately. A clinical trial site reporting an event to the company does not pause or absorb the company’s own reporting deadline.

4. Practical recommendations

• Build a matrix of “party × report type × deadline”: manufacturer / importer (10 days / 30 days), hospital (30 days, running from documentation of the incident), researcher (72 hours).
• Establish the importer’s reporting process separately, without reliance on the manufacturer.
• Set the distributor’s transmission timeframe to the manufacturer or importer at the highest risk tier.
• In ITA projects, manage the researcher’s 72-hour process and the company’s own 10-day / 30-day process in parallel.
• Archive all reports and hand-over records so that a traceable chain exists across the supply chain.

5. Verification checklist

• □ A “party × report type × deadline” matrix has been established
• □ The importer has established its reporting process independently
• □ The distributor’s transmission timeframe has been set at the highest risk tier
• □ The ITA 72-hour process and the 10-day / 30-day process have been established in parallel
• □ The hospital reporting pathway (where applicable) has been incorporated into supply chain communication
• □ Reports and hand-over records have been archived

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com